EUVIMEDEUVIMED entdecken
Crossref

Dynamic path analysis for exploring treatment effect mediation processes in clinical trials with time‐to‐event endpoints

Matthias Kormaksson, Markus Reiner Lange, David Demanse, Susanne Strohmaier, Jiawei Duan, Qing Xie, Mariana Carbini, Claudia Bossen, Achim Guettner, Antonella Maniero

Statistics in Medicine · 2024

DOI: 10.1002/sim.10191 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Statistics in Medicine, 2024. Verfasst von Matthias Kormaksson und 9 weiteren Autor:innen. Beteiligte Einrichtung: Analytics, Development, Novartis Pharma AG, Basel, Switzerland. Hauptthemen laut MEDLINE: Mediation Analysis. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 34 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Why does a beneficial treatment effect on a longitudinal biomarker not translate into overall treatment benefit on survival, when the biomarker is in fact a prognostic factor of survival? In a recent exploratory data analysis in oncology, we were faced with this seemingly paradoxical result. To address this problem, we applied a theoretically principled methodology called dynamic path analysis, which allows us to perform mediation analysis with a longitudinal mediator and survival outcome. The aim of the analysis is to decompose the total treatment effect into a direct treatment effect and an indirect treatment effect mediated through a carefully constructed mediation path. The dynamic nature of the underlying methodology enables us to describe how these effects evolve over time, which can add to the mechanistic understanding of the underlying processes. In this paper, we present a detailed description of the dynamic path analysis framework and illustrate its application to survival mediation analysis using simulated and real data. The use case analysis provides clarity on the specific exploratory question of interest while the methodology generalizes to a wide range of applications in drug development where time‐to‐event is the primary clinical outcome of interest.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Mediation AnalysisHumansSurvival AnalysisComputer SimulationTreatment OutcomeModels, StatisticalClinical Trials as TopicEndpoint DeterminationBiomarkers

Stichwörter der Autor:innen

direct effectsdynamic path analysisindirect effectstotal effects

Substanzen

Biomarkers

Autor:innen und Institutionen

  • Analytics, Development, Novartis Pharma AG, Basel, Switzerland.
  • Department of Epidemiology, Medical University of Vienna, Vienna, Austria.
  • Analytics, Development, Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, USA.

Zitieren

APA

Kormaksson, M., Lange, M. R., Demanse, D., Strohmaier, S., Duan, J., Xie, Q., Carbini, M., Bossen, C., Guettner, A., & Maniero, A. (2024). Dynamic path analysis for exploring treatment effect mediation processes in clinical trials with time‐to‐event endpoints. Statistics in Medicine. https://doi.org/10.1002/sim.10191

Vancouver

Kormaksson M, Lange MR, Demanse D, Strohmaier S, Duan J, Xie Q, et al. Dynamic path analysis for exploring treatment effect mediation processes in clinical trials with time‐to‐event endpoints. Statistics in Medicine. 2024. doi:10.1002/sim.10191

BibTeX
@article{Kormaksson2024,
  author = {Kormaksson, Matthias and Lange, Markus Reiner and Demanse, David and Strohmaier, Susanne and Duan, Jiawei and Xie, Qing and Carbini, Mariana and Bossen, Claudia and Guettner, Achim and Maniero, Antonella},
  title = {Dynamic path analysis for exploring treatment effect mediation processes in clinical trials with time‐to‐event endpoints},
  journal = {Statistics in Medicine},
  year = {2024},
  doi = {10.1002/sim.10191}
}
Kostenlos starten →